common.study.topics.clinical

Carotenoid Supplementation During Pregnancy

common.study.values.description

Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects

This study is designed to test the hypotheses that (1) the third trimester of pregnancy is a period of maternal systemic and ocular carotenoid depletion; (2) prenatal supplementation with 6.0 milligrams of lutein and 0.5 milligrams of zeaxanthin will have significant effects on ocular and systemic biomarkers of maternal and infant carotenoid status relative to a matched, standard-of-care prenatal supplement without added lutein and zeaxanthin; and (3) newborn infants with the highest systemic and ocular carotenoid status will have more mature foveal structure. Mothers will be enrolled in the study during their first trimester, and will take the study carotenoid or control supplements for 6 to 8 months. The final study outcome measurements of mothers and infants will be completed within two weeks of the baby's birth.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Carotenoid Group

DHA Softgel active ingredients: DHA 200 mg, d-Alpha Tocopherol 30 IU, Lutein 6mg

Dietary Supplement - Control Group

DHA Softgel active ingredients: DHA 200 mg, d-Alpha Tocopherol 30 IU

participant.views.study.view.additional

participant.views.study.view.scientific-title

Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects

common.study.values.clinical-trial-id

NCT03750968

participant.views.study.view.id

av2mra